Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin Dilger

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Therapeutic Drug Monitoring|February 17, 2007
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazineKarin Dilger, Elke Schaeffeler, Milan Lukas, et al.
Clinical Pharmacokinetics|February 27, 2003
Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxibStefanie S Brenner, Charlotte Herrlinger, Karin Dilger, et al.
Inflammatory Bowel Diseases|October 9, 2004
Pharmacokinetics of mesalazine pellets in children with inflammatory bowel diseaseHeleen Wiersma, Johanna C Escher, Karin Dilger, et al.
Journal of Hepatology|March 15, 2012
Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and healthKarin Dilger, Simon Hohenester, Ursula Winkler-Budenhofer, et al.
United European Gastroenterology Journal|February 14, 2018
Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trialAxel Dignass, Robert Schnabel, Jacek Romatowski, et al.
Journal of Crohn'S & Colitis|February 19, 2014
Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trialAxel Dignass, Simeon Stoynov, Andrey E Dorofeyev, et al.
Journal of Crohn'S & Colitis|April 2, 2011
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trialVolker Gross, Ivan Bunganic, Elena A Belousova, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 9, 2014
The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-studyWolfgang Kreisel, Peter Deibert, Limas Kupcinskas, et al.
Gut|June 17, 2010
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialWalter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch, et al.
Inflammatory Bowel Diseases|February 8, 2013
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levelsSieglinde Angelberger, Elke Schaeffeler, Alexander Teml, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Therapeutic Drug Monitoring|February 17, 2007
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazineKarin Dilger, Elke Schaeffeler, Milan Lukas, et al.
Clinical Pharmacokinetics|February 27, 2003
Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxibStefanie S Brenner, Charlotte Herrlinger, Karin Dilger, et al.
Inflammatory Bowel Diseases|October 9, 2004
Pharmacokinetics of mesalazine pellets in children with inflammatory bowel diseaseHeleen Wiersma, Johanna C Escher, Karin Dilger, et al.
Journal of Hepatology|March 15, 2012
Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and healthKarin Dilger, Simon Hohenester, Ursula Winkler-Budenhofer, et al.
United European Gastroenterology Journal|February 14, 2018
Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trialAxel Dignass, Robert Schnabel, Jacek Romatowski, et al.
Journal of Crohn'S & Colitis|February 19, 2014
Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trialAxel Dignass, Simeon Stoynov, Andrey E Dorofeyev, et al.
Journal of Crohn'S & Colitis|April 2, 2011
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trialVolker Gross, Ivan Bunganic, Elena A Belousova, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 9, 2014
The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-studyWolfgang Kreisel, Peter Deibert, Limas Kupcinskas, et al.
Gut|June 17, 2010
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialWalter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch, et al.
Inflammatory Bowel Diseases|February 8, 2013
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levelsSieglinde Angelberger, Elke Schaeffeler, Alexander Teml, et al.
Pageof 3